Company: HURA
Filing Date: 2025-08-12
Form Type: S-1
Source: 0001193125-25-179009
Chunk: 302

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-08-12
Form: S-1
Chunk 302
---
     |                                                   6 |
| 30.50to48.00     |                 |     |                                                  80 |     |     |                                             7.14 |     |     |                                                  47 |
| 62.00to68.50     |                 |     |                                                  14 |     |     |                                             6.81 |     |     |                                                  14 |
| 85.00            |                 |     |                                                   9 |     |     |                                             5.43 |     |     |                                                   9 |
| 304.95to2,660.00 |                 |     |                                                   1 |     |     |                                             2.33 |     |     |                                                   1 |
|                  |                 |     |                                                 237 |     |     |                                                  |     |     |                                                 101 |

<div align='center'>F-6 2</div>

Kintara Therapeutics, Inc. Notes to Condensed Consolidated Interim Financial Statements (Unaudited) December 31, 2023 (expressed in US dollars and in thousands, except par value and per share amounts, unless otherwise noted)

Stock options granted during the six months ended December 31, 2023, have been valued using a Black-Scholes pricing model with the following assumptions:

|                         |     | December 31, 2023 |       |   |
|:------------------------|:----|:------------------|------:|:--|
| Dividend rate           |     |                   |     — | % |
| Estimated volatility    |     |                   | 91.40 | % |
| Risk-free interest rate |     |                   |  4.24 | % |
| Expected term - years   |     |                   |  6.08 |   |

The estimated volatility of the Company’s common stock at the date of issuance of the stock options is based on the historical volatility of the Company. The risk-free interest rate is based on rates published by the government for bonds with a maturity similar to the expected remaining term of the stock options at the valuation date. The expected term of the stock options has been estimated using the plain vanilla method.

The Company has recognized the following amounts as stock option expense for the periods noted (in thousands):

|                            |     | Three months endedDecember 31, |     |     |       |     |     | Six months endedDecember 31, |     |     |       |     |
|